Regan J. Lauer - Jan 31, 2024 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Chief Accounting Officer
Signature
/s/ Jason Liljestrom, as Attorney-in-Fact
Stock symbol
IBRX
Transactions as of
Jan 31, 2024
Transactions value $
-$45,259
Form type
4
Date filed
2/2/2024, 07:32 PM
Previous filing
Dec 19, 2023
Next filing
Feb 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Options Exercise $0 +32.9K +43.87% $0.00 108K Jan 31, 2024 Direct
transaction IBRX Common Stock Tax liability -$45.3K -13.5K -12.49% $3.36 94.3K Jan 31, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Options Exercise $0 -32.9K -100% $0.00* 0 Jan 31, 2024 Common Stock 32.9K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2 Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award vested on January 31, 2024.